HOME >> MEDICINE >> NEWS
Dutch study highlights short-term and long-term options for treatment of tennis elbow

N.B. Please note that if you outside North America the embargo date for Lancet press material is 0001 hours UK time Friday 22 February 2002.

Authors of a study in this weeks issue of THE LANCET conclude that steroid injections offer the best short-term treatment for tennis elbow, with physiotherapy offering marginally better long-term results than a wait-and-see policy.

Tennis elbow (lateral epicondylitis) affects 1-3% of the adult population; symptoms usually last between 6 months and two years, with most patients making a full recovery. The condition is generally treated with corticosteroid injections or physiotherapy. However, Dutch clinical guidelines recommend a wait-and-see policy.

Nynke Smidt and colleagues from Vrije University, Amsterdam, Netherlands, studied patients with tennis elbow of at least 6 weeks duration who were recruited by family doctors. Patients were randomly allocated to 6 weeks of treatment with corticosteroid injections, physiotherapy, or a wait-and-see policy. Outcome measures included general improvement, severity of the main complaint (pain), elbow disability, and patients satisfaction. The severity of elbow complaints, grip strength, and pressure pain threshold were assessed; all outcomes were assessed at 3, 6, 12, 26, and 52 weeks.

185 patients took part in the study. Corticosteroid injections were substantially better than all other therapy options for all outcome measures at 6 weeks; success rates were 92% compared with 47% for physiotherapy and 32% for wait-and-see policy. However, recurrence rate in the injection group was high. Long-term differences between injections and physiotherapy were significantly in favour of physiotherapy; success rates at 52 weeks were 69% for injections, 91% for physiotherapy, and 83% for a wait-and-see policy. However, the better success rate for physiotherapy over a wait-and-see policy was not statistically significant.

Nynke Smidt Comment
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-0-20-7611-4076
Lancet
21-Feb-2002


Page: 1 2

Related medicine news :

1. Dutch study highlights crying as risk factor for child abuse
2. Controlled study after Dutch caf fire highlights teen mental-health problems after disasters
3. Dutch study links tea drinking to reduced heart attack risk
4. Four researchers awarded Dutch Nobel Prize
5. "Dutch Nobel Prize" for three researchers
6. First head-to-head study to compare lidoderm patch and Celebrex in treating pain
7. UMaine study looks at infants and chronic nighttime crying
8. Chronic pain treatments more effective when taken together, new study shows
9. UNC study: Most N.C. family practitioners engage in unrecognized community service
10. New study in Nature demonstrates protection against cell death during heart attack
11. UCSF study offers insight into human circadian rhythms

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/21/2017)... ... January 21, 2017 , ... Pacifica Graduate Institute’s Alumni ... line-up of events for its annual meeting “Coming Home 2017,” an activity-packed weekend ... Home 2017” will be held on Friday January 27 through Sunday, January 29, ...
(Date:1/21/2017)... ... 2017 , ... The Nobel Biocare™ dental implant company is ... its creos™ line of bone regenerative products. Specifically, the Nobel Biocare™ ... creos™ allo.gain™ bone graft for a variety of bone reconstruction procedures. In addition ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a skin ... pure essential oils, announced the company had a successful visit to the 2017 ECRM ... event gives companies that work in the nutritional, sports and health industries a chance ...
(Date:1/20/2017)... ... January 20, 2017 , ... ATP Science, an Australian-based company ... attended the January ECRM Trade Show in Hilton Head, SC, benefiting from outstanding ... range of supplements that keep the body functioning at its peak performance by ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well has launched two ... drinks have been produced in collaboration with Zlatan Ibrahimovic and have been developed ... After a successful launch in Sweden last year, the next generation sports drinks ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... 2017  Palladian Health, a leading provider of ... of an opioid management program which assists physicians ... helps stem the growing tide of dependence on ... chronic non-cancer pain (back pain, neck pain, and ... of evidence regarding long-term effectiveness. The ...
(Date:1/20/2017)... January 20, 2017 Avillion LLP, a co-developer ... Mark Weinberg , MD MBA as Chief Medical Officer. Dr ... USA . ... Dr Weinberg has spent more than 17 years as a ... companies to micro-cap biotech. Over the course of his career, he ...
(Date:1/19/2017)... -- Report Details What can be expected ... to grow at the fastest rates? This visiongain report ... opportunities and prospects. Our 190-page report provides 124 ... in the industry and the future market prospects. Our ... all the major categories of the ophthalmic devices market. ...
Breaking Medicine Technology:
Cached News: